Non-Muscle Invasive Bladder Cancer Patient Survey - Imfinzi (durvalumab)
Bladder Cancer Canada is looking for people with non-muscle invasive bladder cancer and people who have been treated with Imfinzi (durvalumab) to talk about their experience.
The pan-Canadian Oncology Drug Review (pCODR) makes recommendations about whether provincial health plans should pay for new cancer drugs. pCODR will soon be reviewing the use of Imfinzi (durvalumabumab) in combination with BCG (Bacillus Calmette-Guérin) as treatment for non-muscle invasive bladder cancer. Bladder Cancer Canada will be making a submission to ensure that patient voices are represented and considered during the review process. We are looking for patients willing to speak about their experience.
Does this survey apply to you?
This survey is intended for patients with non-muscle invasive bladder cancer. We are also interested in surveying the subgroup of patients who have treatment experience with Imfinzi (durvalumab) in combination with BCG.
Please note that caregivers may answer questions on behalf of the patient where the patient is unable or unavailable.
You do not need to live in Canada to respond to this survey; we appreciate input from every patient.
We are also interested in speaking directly with people who have treatment experience with Imfinzi in combination with BCG. Please contact Michelle Colero, Executive Director at patients@bladdercancercanada.org or by calling 1-866-674-8889 if you would be willing to participate in a brief telephone interview.
We would like to thank everyone for helping to ensure that patient experiences are represented in the cancer drug funding review process.
Privacy Policy: To ensure patient privacy and confidentiality, individual responses will not be identifiable. It is important to note that selected quotations may be used for the final submission to government agencies without reference to patient name or any other information that could lead to identifying the patient.